CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,661 enrolled
Drug / intervention
HPV test +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02067468
NCT02067468N/ACompleted

Evaluation of Strategies for Optimal Clinical Management of Women With Atypical Squamous Cells of Undetermined Significance (ASC-US)

Universidad de Antioquia·interventional·Posted Feb 20, 2014·Updated Sep 19, 2019

In Brief

A clinical study evaluating HPV test, COLPOSCOPY, and 1 other intervention for Cervical Abnormalities and 2 related conditions. Completed, enrolled 2,661 participants across 1 site.

Detailed Summary

Cervical cancer as well cervical preneoplastic abnormalities (CIN2+) are cause by human papillomavirus (HPV) infection. These abnormalities have been historically detected by cervical cytology, but recent evidence shows that HPV testing is superior to cytology to detect cervical lesions that eventually will progress to cancer. Despite evidence, conventional cytology (Pap) remains as a primary screening test in Colombia and HPV test is recommended as a triage test for women with atypical squamous cells of undetermined significance (ASC-US) in settings around the world. Women with ASC-US have low risk to CIN2+ but higher than healthy population, and therefore it is important to provide appropriate clinical management. However, there is no consensus of how to deal women with ASC-US and therefore there are still three strategies for this purpose: 1) immediate colposcopy, 2) repeat conventional cytology at 6 and 12 months and 3) HPV testing. The main objective of this study is to compare the effectiveness and the efficient among the strategies as well as to evaluate the acceptability of the HPV testing in a real-life setting.

Study Details

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 20, 2014
Enrollment StartJan 1, 2011
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 12.4 years ago

Interventions

HPV testdevice

QIAGEN - The Digene HPV test®

COLPOSCOPYprocedure

Colposcopy routine health services

cytologydevice

Cytology routine health services